ResMed Inc. — News

TROY, Mich., July 21, 2026 /PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Broadridge Financial Resources Inc. (NYSE: BR) as its "Stock to Study" and ResMed Inc. (NYSE: RMD) as its "Undervalued Stock" in the October 2026 issue for investors' informational and educational use.

prnewswire.com - 2026-07-21 16:40:00

Baader Bank Aktiengesellschaft decreased its stake in shares of ResMed Inc. (NYSE: RMD) by 61.7% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,768 shares of the medical equipment provider's stock after selling 7,696 shares during the quarter. Baader

defenseworld.net - 2026-07-21 04:01:02

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

zacks.com - 2026-07-13 09:56:21

RMD's MatrixCare sale sharpens its focus on sleep, breathing and connected care while freeing resources for AI-powered digital health.

zacks.com - 2026-07-10 13:56:05

ResMed Inc. (NYSE:RMD) agreed to sell its MatrixCare business on Tuesday to Frazier Healthcare Partners, a private equity firm focused exclusively on health care, for $490 million.

benzinga.com - 2026-07-09 14:03:51

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

zacks.com - 2026-07-08 10:51:05

I track a curated universe of 50 high-quality dividend growth stocks to identify opportune entry points based on valuation and future return potential. Year-to-date through June, the investable universe returned 8.69%, trailing SPY (10.10%) and SCHD (17.50%), but several individual stocks outperformed significantly. Currently, 39 out of 50 stocks offer a forward return estimate of at least 10%, with 22 appearing potentially undervalued by my free cash flow model.

seekingalpha.com - 2026-07-08 07:42:40

ResMed said on Tuesday it would sell its software business MatrixCare to private equity firm Frazier Healthcare Partners for $490 ​million in cash, as the health technology company ‌sharpens its focus on sleep, breathing and home-based care.

reuters.com - 2026-07-07 18:07:23

SEATTLE--(BUSINESS WIRE)--Frazier Healthcare Partners ("Frazier"), a private equity firm focused exclusively on the healthcare industry, today announced it has entered into a definitive agreement to acquire MatrixCare (the “Company”) from Resmed (NYSE & ASX: RMD).MatrixCare is a leading provider of cloud-based EHR software purpose-built for out-of-hospital care settings, including skilled nursing, senior living, home health, hospice, and life plan communities. A multi-year winner of the Best.

businesswire.com - 2026-07-07 17:06:00

SAN DIEGO, July 07, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has entered into a definitive agreement to sell its MatrixCare business to Frazier Healthcare Partners, a private equity firm focused exclusively on health care. This move reflects Resmed's 2030 strategy by focusing on high-growth, scalable opportunities in sleep health, breathing health and connected home-based healthcare.

globenewswire.com - 2026-07-07 16:30:00

ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

zacks.com - 2026-07-07 13:11:12

ResMed (RMD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

zacks.com - 2026-07-07 11:40:17

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

zacks.com - 2026-07-07 10:45:18

ResMed (RMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

zacks.com - 2026-07-01 13:01:04

The mean of analysts' price targets for ResMed (RMD) points to a 28.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

zacks.com - 2026-07-01 10:55:13

SAN DIEGO, June 30, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2026 on Thursday, August 6, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results.

globenewswire.com - 2026-06-30 16:30:00

ResMed (RMD) exemplifies the razor-and-blade model, leveraging inevitability, brand loyalty, inexpensive recurring costs, and a superior user experience. RMD dominates the sleep apnea market with a 62% share in a vast, under-penetrated addressable market with huge future growth potential. RMD's financials are resilient, with consistent sales and earnings growth, no earnings misses in more than a decade, and a predictable business model.

seekingalpha.com - 2026-06-29 17:18:40

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

benzinga.com - 2026-06-17 09:13:10

Futures are trading mixed as we hit the midweek point, as the Space Exploration Technologies (NASDAQ: SPCX) or SpaceX IPO rush is starting to fade somewhat.

247wallst.com - 2026-06-17 08:00:44

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

zacks.com - 2026-06-16 10:46:05

My contrarian take on ResMed is that GLP-1 concerns are overstated, and even though a portion of market share will be lost, the remaining portion will be more beneficial to profitability. Other business threats come from PHG's reentrance and Apnimed's drug commercialization. While not to be overlooked, I still see RMD retaining its market dominance. The stock currently trades as if revenues are already declining and margins are contracting. But the opposite is true. Margins far exceed peers, and the top line grows at double digits.

seekingalpha.com - 2026-06-11 07:05:56

RMD gains from acquisition-led Residential Care Software growth, mask innovation and strong finances but faces macro and competitive pressures.

zacks.com - 2026-06-09 09:55:21

I track a curated universe of 50 high-quality dividend growth stocks to identify attractive entry points based on valuation and forward return potential. Year-to-date, the universe lags SPY and SCHD, but select names like LRCX (+343%) and KLAC (+208%) have dramatically outperformed since inception. Currently, 40 stocks offer forward return estimates of at least 10%, with 24 appearing potentially undervalued by my free cash flow model.

seekingalpha.com - 2026-06-08 04:51:11

On June 04, 2026, ResMed Inc (RMD) shares rose 4.2% today, currently trading at $194.32. The stock has seen a 52-week range between $180.27 and $293.81, highlig

gurufocus.com - 2026-06-04 17:57:00

Angelini Ventures marks its first portfolio exit as ResMed acquires Noctrix Health, validating its strategy of backing breakthrough healthcare innovation.

globenewswire.com - 2026-06-03 07:40:00

ResMed Inc. (RMD) Presents at 46th Annual William Blair Growth Stock Conference Prepared Remarks Transcript

seekingalpha.com - 2026-06-03 04:04:20

SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has completed its acquisition of Noctrix Health, Inc. , a medical device company developing clinically validated wearable therapeutics for chronic neurological disorders.

globenewswire.com - 2026-06-01 16:05:00

Acquisition adds Nidra® Tonic Motor Activation (TOMAC) Therapy, an FDA De Novo classified, nonpharmacologic treatment designed to address moderate-to-severe Restless Legs Syndrome (RLS). Acquisition adds Nidra® Tonic Motor Activation (TOMAC) Therapy, an FDA De Novo classified, nonpharmacologic treatment designed to address moderate-to-severe Restless Legs Syndrome (RLS).

globenewswire.com - 2026-06-01 16:05:00

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

zacks.com - 2026-05-26 10:46:12

Picture a single 73-year-old retiree sitting on $1.3 million in a traditional 401(k), drawing $36,000 a year in Social Security, and feeling reasonably set for retirement.

247wallst.com - 2026-05-24 23:21:12

Picture a 55-year-old earning $400,000 with $1.5 million in a traditional 401(k).

247wallst.com - 2026-05-22 13:47:23

Investors need to pay close attention to RMD stock based on the movements in the options market lately.

zacks.com - 2026-05-20 15:40:31

SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Aaron Bloomer, chief financial officer, will attend the 46th Annual William Blair Growth Stock Conference in Chicago, IL on Tuesday, June 2, 2026. Resmed's webcast presentation will begin at approximately 4:40 p.m. (Central Time).

globenewswire.com - 2026-05-19 16:05:00

Healthcare giants like Eli Lilly, Tandem Diabetes, Intuitive Surgical and ResMed are tapping aging-driven demand in obesity, surgery and sleep care.

zacks.com - 2026-05-19 16:01:09

SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, and ŌURA, maker of the world's leading smart ring, today announced they are partnering to expand access to sleep health education and pathways to care, helping more people sleep better and improve their overall health. Sleep is increasingly recognized as a key pillar of long-term health, yet it remains widely underprioritized.1 Early signs of poor sleep are often dismissed, creating a gap between what people experience and when they seek support or clinical care.

globenewswire.com - 2026-05-19 09:00:00

On May 11, 2026, ResMed Inc (RMD) shares fell 3.9% to a current price of $198.76. This decline comes amid broader market pressures, with the stock now trading c

gurufocus.com - 2026-05-11 20:32:00

Dividend growth stocks have a streak of at least 5 consecutive years of dividend increases. I rank a selection of dividend growth stocks and present the top 10 stocks for consideration. To rank stocks, I do a quality assessment and sort candidates by quality scores. My new quality scoring system rates dividend stocks on a 10-point scale across 9 weighted factors. Each factor blends qualitative signals and quantitative metrics.

seekingalpha.com - 2026-05-09 09:00:00

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

zacks.com - 2026-05-05 10:45:43

Resmed beats Q3 earnings and revenue estimates with strong margin gains, yet shares slip post earnings despite growth across key segments.

zacks.com - 2026-05-01 09:05:31

Revenue: $1.43 billion, an 11% increase year-over-year, 8% in constant currency.Gross Margin: 62.8%, increased by 290 basis points year-over-year.Operating Mar

gurufocus.com - 2026-05-01 02:18:00

Although the revenue and EPS for ResMed (RMD) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

zacks.com - 2026-04-30 18:30:27

ResMed (RMD) came out with quarterly earnings of $2.86 per share, beating the Zacks Consensus Estimate of $2.79 per share. This compares to earnings of $2.37 per share a year ago.

zacks.com - 2026-04-30 18:30:21

Medical device maker ResMed beat third‑quarter profit estimates on Thursday, driven by strong ​demand for its medical devices, while appointing Aaron ‌Bloomer as its new chief financial officer.

reuters.com - 2026-04-30 18:21:41

SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Brett Sandercock, Chief Financial Officer, plans to retire effective May 4, 2026. After conducting a comprehensive search, Aaron Bloomer has been appointed as his successor.

globenewswire.com - 2026-04-30 16:10:00

Revenue increased by 11% to $1.4 billion; up 8% on a constant currency basis  GAAP gross margin up 290 bps to 62.2%; non-GAAP gross margin up 290 bps to 62.8% GAAP income from operations increased 17%; non-GAAP income from operations up 18% GAAP diluted earnings per share of $2.74; non-GAAP diluted earnings per share of $2.86 Operating cash flow of $554 million; $262 million returned to shareholders through share repurchases and dividends Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at  http://investor.resmed.com SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended March 31, 2026.

globenewswire.com - 2026-04-30 16:05:00

Besides Wall Street's top-and-bottom-line estimates for ResMed (RMD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2026.

zacks.com - 2026-04-29 10:15:33

Arizona State Retirement System cut its holdings in shares of ResMed Inc. (NYSE: RMD) by 7.6% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 40,076 shares of the medical equipment provider's stock after selling 3,297 shares during the quarter. Arizona

defenseworld.net - 2026-04-26 03:08:50

ResMed (RMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com - 2026-04-23 11:05:12

RMD gears up for fiscal Q3 earnings with steady estimates, rising demand in sleep devices and AI-driven digital health tools poised to shape results.

zacks.com - 2026-04-23 10:11:21